{"address1": "Kalvebod Brygge 43", "city": "Copenhagen", "zip": "1560", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 1660, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 61, "title": "Co-Founder, Pres & CEO", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 2775744, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Pagano", "age": 44, "title": "Exec. VP & CFO", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": 1033522, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony  Mancini", "age": 51, "title": "Exec. VP & COO", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 1122109, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin  Schultz", "age": 46, "title": "Sr. Director of Clinical Operations  & Non-Independent Director", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": 73823, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Judith V. Klimovsky M.D.", "age": 64, "title": "Exec. VP & Chief Devel. Officer", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 1166403, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tahamtan  Ahmadi", "age": 49, "title": "Exec. VP, Chief Medical Officer & Head of Experimental Medicines", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": 1107345, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mijke  Zachariasse Ph.D.", "age": 48, "title": "Sr. Director, Head of Antibody Research Materials & Non-Independent Director", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": 147646, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Takahiro  Hamatani", "age": 47, "title": "Sr. Director of Fin. Japan & Non-Independent Director", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 73823, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Carlsen", "title": "Sr. Director, VP & Head of Investor Relations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Birgitte  Stephensen M.Sc.", "age": 61, "title": "Exec. VP & Chief Legal Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 1, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 398.9, "open": 402.56, "dayLow": 396.25, "dayHigh": 404.75, "regularMarketPreviousClose": 398.9, "regularMarketOpen": 402.56, "regularMarketDayLow": 396.25, "regularMarketDayHigh": 404.75, "payoutRatio": 0.0, "beta": 0.726499, "trailingPE": 32.284092, "forwardPE": 29.58579, "volume": 219, "regularMarketVolume": 219, "averageVolume": 293, "averageVolume10days": 200, "averageDailyVolume10Day": 200, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 26187034624, "fiftyTwoWeekLow": 260.25, "fiftyTwoWeekHigh": 470.5, "priceToSalesTrailing12Months": 1.7942469, "fiftyDayAverage": 383.4866, "twoHundredDayAverage": 385.8801, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 4349741056, "profitMargins": 0.37835, "floatShares": 64540752, "sharesOutstanding": 65222500, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.49715, "impliedSharesOutstanding": 0, "bookValue": 419.769, "priceToBook": 0.9529048, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": -0.184, "netIncomeToCommon": 5521999872, "trailingEps": 12.39, "forwardEps": 13.52, "pegRatio": 67.46, "enterpriseToRevenue": 0.298, "enterpriseToEbitda": 0.647, "52WeekChange": 0.38338828, "SandP52WeekChange": 0.046755195, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "GNMSF", "underlyingSymbol": "GNMSF", "shortName": "GENMAB AS", "longName": "Genmab A/S", "firstTradeDateEpochUtc": 1262701800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bc5ee846-4743-31f0-a550-ee0aa32fbaca", "messageBoardId": "finmb_665704", "gmtOffSetMilliseconds": -14400000, "currentPrice": 399.9999, "targetHighPrice": 383.57, "targetLowPrice": 383.57, "targetMeanPrice": 383.57, "targetMedianPrice": 383.57, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 22324000768, "totalCashPerShare": 341.494, "ebitda": 6719000064, "totalDebt": 597000000, "quickRatio": 15.566, "currentRatio": 15.566, "totalRevenue": 14595000320, "debtToEquity": 2.175, "revenuePerShare": 223.208, "returnOnAssets": 0.14559, "returnOnEquity": 0.2225, "grossProfits": 14595000000, "freeCashflow": 2091750016, "operatingCashflow": 3912000000, "earningsGrowth": -0.184, "revenueGrowth": 0.996, "grossMargins": 1.0, "ebitdaMargins": 0.46036, "operatingMargins": 0.43816003, "financialCurrency": "DKK", "trailingPegRatio": 1.3246}